fH1 2 ug

Phase 1Biologic

SSumitomo Pharma Co., Ltd.

fH1 2 ug is one of 19 biologic programs targeting Influenza. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InfluenzaActive, not recruiting

InfluenzaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1053 competitors in Influenza

#DrugCompanyPhaseTrials

Fluzone

Sanofi

Preclinical

16 2

Fluzone

GSK

Preclinical

37 3

Trexall

Alnylam Pharmaceuticals

Preclinical

1 4

Crestor

AstraZeneca

Preclinical

1 5

Avigan

AAppili Therapeutics Inc.

Preclinical

6 6

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

30 7

COMIRNATY

Pfizer

Preclinical

1 8

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

1 9

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

14 10

fH1 2 ug

SSumitomo Pharma Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Influenza1 trial

First-in-human Study to Assess the Safety, Tolerability and Immunogenicity of the Adjuvanted Universal Influenza Vaccine fH1/DSP-0546LP

Active, not recruiting·SSumitomo Pharma Co., Ltd.·Phase 1·NCT06460064·144 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for fH1 2 ug. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — fH1 2 ug compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for fH1 2 ug. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sumitomo Pharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SSumitomo Pharma Co., Ltd.

fH1 2 ug

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Influenza1 trial

References

Drug Info

Quick Facts

Related News